Cadila Healthcare has just announced that its unit Zydus had signed a collaborative agreement with TLC of Taiwan. As part of the agreement, Cadila Healthcare will market its Liposomal Amphotericin-B; a critical drug to treat Black Fungus in India, that is manufactured by TLC of Taiwan.
TLC is a specialty Taiwanese pharma company. Under the terms of the agreement, TLC will manufacture and also supply AmphoTLC on non-exclusive basis to Zydus, and Zydus will commercialize the drug in India. This has become a kind of an emergency after the surge in Black Fungus infections in India. This drug will also address the acute shortage of amphotericin-B in India and help avert the after effects of COVID.
Cadila Healthcare has just announced that its unit Zydus had signed a collaborative agreement with TLC of Taiwan. As part of the agreement, Cadila Healthcare will market its Liposomal Amphotericin-B; a critical drug to treat Black Fungus in India, that is manufactured by TLC of Taiwan.
TLC is a specialty Taiwanese pharma company. Under the terms of the agreement, TLC will manufacture and also supply AmphoTLC on non-exclusive basis to Zydus, and Zydus will commercialize the drug in India. This has become a kind of an emergency after the surge in Black Fungus infections in India. This drug will also address the acute shortage of amphotericin-B in India and help avert the after effects of COVID.